Candida auris Isolates Resistant to Three Classes of Antifungal Medications – New York, 2019.

January 30, 2020 at 3:42 pm

MMWR Morb Mortal Wkly Rep. January 10, 2020 V.69 N.1 P.6-9.  

Ostrowsky B, Greenko J, Adams E, Quinn M, O’Brien B, Chaturvedi V, Berkow E, Vallabhaneni S, Forsberg K, Chaturvedi S, Lutterloh E, Blog D; C. auris Investigation Work Group.

Abstract

Candida auris is a globally emerging yeast that causes outbreaks in health care settings and is often resistant to one or more classes of antifungal medications (1).

Cases of C. auris with resistance to all three classes of commonly prescribed antifungal drugs (pan-resistance) have been reported in multiple countries (1).

C. auris has been identified in the United States since 2016; the largest number (427 of 911 [47%]) of confirmed clinical cases reported as of October 31, 2019, have been reported in New York, where C. auris was first detected in July 2016 (1,2).

As of June 28, 2019, a total of 801 patients with C. auris were identified in New York, based on clinical cultures or swabs of skin or nares obtained to detect asymptomatic colonization (3).

Among these patients, three were found to have pan-resistant C. auris that developed after receipt of antifungal medications, including echinocandins, a class of drugs that targets the fungal cell wall.

All three patients had multiple comorbidities and no known recent domestic or foreign travel.

Although extensive investigations failed to document transmission of pan-resistant isolates from the three patients to other patients or the environment, the emergence of pan-resistance is concerning.

The occurrence of these cases underscores the public health importance of surveillance for C. auris, the need for prudent antifungal prescribing, and the importance of conducting susceptibility testing on all clinical isolates, including serial isolates from individual patients, especially those treated with echinocandin medications.

This report summarizes investigations related to the three New York patients with pan-resistant infections and the subsequent actions conducted by the New York State Department of Health and hospital and long-term care facility partners.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973342/pdf/mm6901a2.pdf

Entry filed under: Antimicoticos, BIOFILM - BIOPELICULAS, Biología Molecular, Epidemiología, Health Care-Associated Infections, Infecciones emergentes, Infecciones micoticas, Infecciones nosocomiales, Metodos diagnosticos, REPORTS, Sepsis, Update.

PERSPECTIVE – A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.


Calendar

January 2020
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Most Recent Posts


%d bloggers like this: